Lonza expands PyroCell pyrogen testing portfolio with two new rapid systems

Published: 25-Oct-2023

Lonza has launched PyroCell MAT Rapid System and PyroCellMAT Human Serum (HS) Rapid System, two sustainable monocyte activation test (MAT) systems containing the new PeliKine Human IL-6 Rapid ELISA Kit

Lonza has launched two new rapid monocyte activation test (MAT) systems, the PyroCell (registered trademark) MAT Rapid System and PyroCell MAT Human Serum (HS) Rapid System, to streamline and simplify rabbit-free pyrogen testing.

The systems, which will replace Lonza’s current MAT system kit offerings, contain the new PeliKine Human IL-6 Rapid ELISA Kit that minimises hands-on time and reduces time-to-results from two days to two hours. The new tests give pharma manufacturers easier, faster, and more efficient MAT testing options for product safety testing while helping to reduce the reliance on animals.

We’ve leveraged our long collaboration with Essange Reagents, formerly Sanquin Reagents, to deliver the new PyroCell MAT Rapid Systems, offering customers two MAT solutions that are easier to execute. Transitioning to rabbit-free, sustainable pyrogen testing has never been simpler

- Orla Cloak, VP, Head of Bioprocessing Solutions

Historically, pyrogen testing of pharmaceuticals has relied on the Rabbit Pyrogen Test (RPT), an unsustainable method requiring significant time-to-results. Pharma manufacturers now face growing pressure to discontinue the RPT due to ethical concerns, regulatory initiatives, and directives to increase the efficiency of QC pyrogen testing programmes.

Lonza expands PyroCell pyrogen testing portfolio with two new rapid systems

Lonza’s PyroCell MAT Rapid Systems, with the new PeliKine Human IL-6 Rapid ELISA Kit, help streamline QC testing workflows. The new ELISA kit contains pre-coated plates and an improved protocol with combined incubation steps, minimising hands-on time and reducing time-to-results to just two hours. The new rapid ELISA kit results are comparable to the current industry standard, making switching to the new test simple for customers. Most critically, the new rapid ELISA kit has been specifically validated for use with the MAT.

Orla Cloak, VP, Head of Bioprocessing Solutions, Lonza, said: “With the RPT set to be discontinued in Europe by 2026, and sustainability a growing focus, pharmaceutical manufacturers are looking to adopt an RPT replacement. We’ve leveraged our long collaboration with Essange Reagents, formerly Sanquin Reagents, to deliver the new PyroCell MAT Rapid Systems, offering customers two MAT solutions that are easier to execute. Transitioning to rabbit-free, sustainable pyrogen testing has never been simpler.”

Lonza will discontinue its current PyroCell MAT System and PyroCell MAT Human Serum (HS) System by early 2024.

Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.
  2. You need to be a subscriber to read this article.
    Click here to find out more.
  3. You need to be a subscriber to read this article.
    Click here to find out more.

You may also like